ALRN

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

Aileron Therapeutics: Low Cash Balance, Early Stage, But Scientific Premise Is Interesting

7 Penny Stocks That Actually Have Buy Ratings

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners